Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Equity Average (2017 - 2025)

Protagonist Therapeutics' Equity Average history spans 9 years, with the latest figure at $630.1 million for Q4 2025.

  • For Q4 2025, Equity Average rose 4.38% year-over-year to $630.1 million; the TTM value through Dec 2025 reached $630.1 million, up 4.38%, while the annual FY2025 figure was $645.0 million, 27.47% up from the prior year.
  • Equity Average for Q4 2025 was $630.1 million at Protagonist Therapeutics, down from $656.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $682.2 million in Q1 2025 and bottomed at $215.9 million in Q1 2023.
  • The 5-year median for Equity Average is $317.1 million (2021), against an average of $409.2 million.
  • The largest annual shift saw Equity Average surged 277.86% in 2021 before it decreased 28.25% in 2023.
  • A 5-year view of Equity Average shows it stood at $314.8 million in 2021, then dropped by 27.07% to $229.6 million in 2022, then soared by 39.11% to $319.4 million in 2023, then soared by 88.97% to $603.6 million in 2024, then grew by 4.38% to $630.1 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Equity Average are $630.1 million (Q4 2025), $656.7 million (Q3 2025), and $678.5 million (Q2 2025).